Drug Development

Merck’s Ebola vaccine promises to stop the next outbreak in its tracks

The last Ebola outbreak ended months ago. But it will be back, and next time there will be an effective vaccine to halt the virus before it can spread. The vaccine is Merck’s rVSV-ZEBOV, which proved to be 100% effective in blocking outbreaks.

Investigators tested the vaccine in what was called a cluster-randomized ring vaccination trial, vaccinating everyone who may have come in contact with a victim. The researchers, reporting in The Lancet, concluded: “The results add weight to the interim assessment that rVSV-ZEBOV offers substantial protection against Ebola virus disease, with no cases among vaccinated individuals from day 10 after vaccination in both randomised and non-randomised clusters.”


Get Endpoints News in your inbox

News reports for those who discover, develop, and market drugs. Join 13,500+ biopharma pros who read Endpoints News articles by email every day. Free subscription.

Quick Subscribe

You're subscribing to Endpoints News

John Carroll, Editor and Co-Founder

We produce two daily newsletters designed to give you a complete picture of what's important in biopharma.

Early Edition is a skimmable digest of original sources you need to see by ~7:15a ET, and our Main Edition is the daily chronicle of biotech, with every story inside the email ~11:55a ET.
2x/weekdays. Privacy policy





Bracket